Companies Under Fire Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Companies Under Fire

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: flint who started this subject	3/29/2002 5:56:41 PM
From: flint	of 10

BMY 3/26/02 sbclasslaw.com The complaint charges Bristol-Myers Squibb Company and certain of its officers and directors with violating the federal securities laws by making itself, and allowing its drug development partner to make, without correction, materially false and misleading statements about the progress of its Erbitux cancer treatment drug’s application for FDA approval even as BRISTOL-MYERS knew that the application and data were false. Specifically, the complaint alleges that on December 28, 2001, a press release disclosed that the FDA had rejected the filing of a Biologics License Application for Erbitux. On January 4, 2002, The Cancer Letter reported that the FDA repeatedly informed defendants about problems with the Erbitux clinical trials during the Class Period. These shocking revelations caused the stock to plummet from a Class Period high of $56 to below $50 -- and now to $40.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next